Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Other Operating Expenses (2021 - 2025)

Oncology Institute's Other Operating Expenses history spans 5 years, with the latest figure at $119.9 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 38.78% year-over-year to $119.9 million; the TTM value through Dec 2025 reached $429.3 million, up 25.33%, while the annual FY2025 figure was $429.3 million, 25.33% up from the prior year.
  • Other Operating Expenses reached $119.9 million in Q4 2025 per TOI's latest filing, up from $118.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $119.9 million in Q4 2025 to a low of $39.0 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $71.7 million, with a median of $69.5 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: soared 83.14% in 2023, then rose 4.75% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $44.6 million in 2021, then soared by 48.94% to $66.5 million in 2022, then increased by 8.59% to $72.2 million in 2023, then rose by 19.71% to $86.4 million in 2024, then skyrocketed by 38.78% to $119.9 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Other Operating Expenses are $119.9 million (Q4 2025), $118.4 million (Q3 2025), and $103.1 million (Q2 2025).